VCEL

Vericel Corp Ord

VCEL.US vcel.com + Research + Basket
CIK 0000887359
Employees 398
Phone 617 588 5555
Fiscal year end December
IPO Feb 04, 1997
Address 25 Blue Sky Drive, Burlington, MA, United States, 01803
41.81
-1.10 (-2.56%)
USD · NASDAQ
52-week range
28.95
49.32
Trading at 63% of the 52-week range
Market Cap
2.20B
P/E Ratio
91.30
Forward P/E
60.24
Book Value
7.23
Div. Yield
N/A
% Institutions
110.21%
% Insiders
1.19%

1 Year

+23.0%

3 Year

+24.8%

10 Year

+1,850.5%
Description

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.

Actions

Add an action for VCEL.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Dominick C. Colangelo Esq. CEO, President & Director 1964
Mr. Joseph Anthony Mara Jr. CFO & Treasurer 1976
Mr. Michael Halpin Chief Operating Officer 1962
Mr. Sean C. Flynn Chief Legal Officer 1974
Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B. Chief Medical Officer 1962
Mr. Jonathan D. Siegal Principal Accounting Officer, VP & Corporate Controller NA
Mr. Eric Burns Vice President of Finance & Investor Relations NA
Mr. Roland DeAngelis Chief Marketing Officer NA
Mr. Patrick J. Fowler Senior Vice President of Corporate Development & Strategy NA
Mr. Mike Gilligan Senior Vice President of Sales NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Apr 02, 2026 Jonathan Mark Hopper N/A Sale 3.47K $35.00 $121.52K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 8.09M Jun 30, 2026 15.80% $0.01 4.21%
State Street Corp 3.29M Jun 30, 2026 6.43% $0.00 4.50%
Congress Asset Management Company, LLP 2.92M Jun 30, 2026 5.70% $0.80 93.53%
Vanguard Capital Management, LLC 2.26M Jun 30, 2026 4.41% $0.00 1.12%
Conestoga Capital Advisors, LLC 2.08M Jun 30, 2026 4.07% $2.02 -15.41%
William Blair Investment Management, LLC 1.99M Jun 30, 2026 3.89% $0.27 8.74%
BNP Paribas Investment Partners SA 1.64M Jun 30, 2026 3.20% $0.07 -4.85%
GW&K Investment Management, LLC 1.55M Jun 30, 2026 3.03% $0.54 -4.10%
Soleus Capital Management, L.P. 1.46M Jun 30, 2026 2.85% $2.24 -42.76%
Geode Capital Management, LLC 1.34M Jun 30, 2026 2.62% $0.00 6.88%
Geneva Capital Management 1.34M Jun 30, 2026 2.62% $1.37 -18.68%
Loomis, Sayles & Company LP 1.20M Jun 30, 2026 2.34% $0.07 23.05%
Vanguard Portfolio Management, LLC 1.06M Jun 30, 2026 2.07% $0.00 6.97%
Bank of America Corp 1.02M Jun 30, 2026 1.98% $0.00 -7.52%
Dimensional Fund Advisors, Inc. 906.20K Jun 30, 2026 1.77% $0.01 7.27%
Silvercrest Asset Management Group LLC 896.65K Jun 30, 2026 1.75% $0.26 -6.52%
Royal Bank of Canada 775.76K Jun 30, 2026 1.52% $0.01 -12.06%
Champlain Investment Partners, LLC 755.83K Jun 30, 2026 1.48% $0.86 -7.28%
Aberdeen Group PLC 710.24K Jun 30, 2026 1.39% $0.04 3.82%
Delaware Management Holdings Inc 664.31K Jun 30, 2026 1.30% $0.04 5.30%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 iShares Core S&P Small-Cap ETF 3.05M 5.95% ▲ 0.02% Sep 30, 2026
2 Vanguard MStar Total Stk Mkt Idx Invest 1.63M 3.18% ▲ 0.44% Sep 30, 2026
3 iShares Russell 2000 ETF 1.33M 2.59% ▼ 1.14% Sep 30, 2026
4 Congress Small Cap Growth Institutional 1.17M 2.28% ▲ 0.00% Sep 30, 2026
5 State Street® SPDR® S&P® Biotech ETF 1.11M 2.17% ▼ 1.88% Sep 30, 2026
6 Conestoga Small Cap Investors 1.05M 2.05% ▼ 9.22% Aug 31, 2026
7 BNP Paribas US Small Cap ClassicC 832.14K 1.63% ▼ 0.19% Aug 31, 2026
8 BNP Paribas Health Cr Innovtr Cl Cap 689.98K 1.35% ▼ 0.02% Aug 31, 2026
9 Loomis Sayles Small Cap Growth Instl 688.15K 1.34% ▲ 7.26% Aug 31, 2026
10 Fidelity Small Cap Index 563.20K 1.10% ▲ 0.85% Jul 31, 2026

Financial Highlights

▼
Market Cap: $2.20B
EBITDA: $31.15M
P/E Ratio: $91.30
PEG Ratio: $0.00
Book Value: $7.23
Earnings/Share: $0.47
Profit Margin: 7.91%
Operating Margin: 0.56%
ROA (TTM): 2.43%
ROE (TTM): 7.16%
Revenue (TTM): $306.30M
Revenue/Share (TTM): $6.04
Earnings Growth (YOY): 18.90%
Revenue Growth (YOY): 22.50%

Valuation Metrics

Enterprise Value: $2.13B
Trailing P/E: 91.30
Forward P/E: 60.24

Shares Statistics

Shares Outstanding: 51.21M
Shares Float: 50.58M
% Insiders: 1.19%
% Institutions: 110.21%
Shares Short: 5.24M
Shares Short (Prior Month): 5.20M
Short Ratio: 9.42
Short % Float: 13.18%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$276.26M
Cost of Goods Sold
adjust
$-70.66M
Gross Profit
subtotal
$205.60M
SG&A
adjust
$-166.99M
R&D
adjust
$-27.56M
Operating Income
subtotal
$11.04M
Other / Non-Operating Items
adjust
$5.47M
Net Income
subtotal
$16.52M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about VCEL.US!